TA
IPXL

Tamarack Advisers’s Impax Laboratories, Inc. IPXL Stock Holding History

Tamarack Advisers’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-257,500
Closed -$3.41M – 37
2016
Q4 		$3.41M Buy
+257,500
New +$4.4M 2.41% 20

Other funds holding IPXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Tamarack Advisers's IPXL Position: Q1 2017 in Review

Tamarack Advisers sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 257,500 shares — an estimated $3.41M sold.

Tamarack Advisers first reported a position in IPXL in Q4 2016 and held it in 1 quarter. The position peaked at $3.41M in Q4 2016. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

  • Tamarack Advisers reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
  • Tamarack Advisers sold 257,500 Impax Laboratories, Inc. shares in Q1 2017, an estimated $3.41M.
  • Tamarack Advisers first reported a position in Impax Laboratories, Inc. in Q4 2016 and held it in 1 quarter.
  • Tamarack Advisers's Impax Laboratories, Inc. position peaked at $3.41M in Q4 2016.
  • 178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on Tamarack Advisers's 13F filing for Q1 2017, filed 12 May 2017.